Motley Fool Wealth Management LLC Has $13.37 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Motley Fool Wealth Management LLC has reduced its holdings in Thermo Fisher Scientific Inc. by 6.8%, owning 26,869 shares worth approximately $13.37 million as of the end of the last quarter.
• Recent transactions by institutional investors include a massive stake increase of 60,610.9% by GAMMA Investing LLC, which now owns over 2.4 million shares valued at $1.2 billion.
• Broker recommendations for Thermo Fisher Scientific include a target price range of $490.00 to $610.00, with a consensus rating of "Moderate Buy" among analysts.

Motley Fool Wealth Management LLC trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,869 shares of the medical research company's stock after selling 1,966 shares during the quarter. Motley Fool Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $13,370,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cypress Advisory Group LLC bought a new position in Thermo Fisher Scientific during the 4th quarter valued at $253,000. GAMMA Investing LLC boosted its stake in Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares in the last quarter. Deutsche Bank AG boosted its stake in Thermo Fisher Scientific by 9.5% during the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after purchasing an additional 114,277 shares in the last quarter. Hancock Whitney Corp boosted its stake in Thermo Fisher Scientific by 0.6% during the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock valued at $2,802,000 after purchasing an additional 30 shares in the last quarter. Finally, Cetera Trust Company N.A boosted its stake in Thermo Fisher Scientific by 3.3% during the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock valued at $2,312,000 after purchasing an additional 150 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TMO shares. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Barclays raised their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Finally, Royal Bank Of Canada reduced their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Activity

In other news, CEO Marc N. Casper sold 8,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $454.45, for a total value of $3,635,600.00. Following the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $52,340,824.30. This trade represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,400 shares of company stock worth $8,345,792. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Up 1.0%

Thermo Fisher Scientific stock traded up $5.06 during mid-day trading on Friday, hitting $490.10. 1,038,000 shares of the company's stock were exchanged, compared to its average volume of 2,488,678. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market cap of $185.07 billion, a P/E ratio of 28.34, a P/E/G ratio of 2.59 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The stock has a 50 day moving average of $433.08 and a two-hundred day moving average of $461.44.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.37 earnings per share. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.